David Fritz, MD
Interventional Pain Medicine · Antioch, TNNPI 1396970331
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 287 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Abbott$1K
- Collegium Pharmaceutical, Inc.$658
- Boston Scientific$597
- Nevro Corp.$525
- Scilex Pharmaceuticals Inc.$516
- plus $1K from 21 others
What the payments were for
- Food & beverage$5,763100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $1,140 |
| Abbott | 34 | $1,088 |
| Collegium Pharmaceutical, Inc. | 47 | $658 |
| Boston Scientific | 23 | $597 |
| Nevro Corp. | 14 | $525 |
| Scilex Pharmaceuticals Inc. | 25 | $516 |
| Protega Pharmaceutials Inc | 9 | $186 |
| Zyla Life Sciences, Inc. | 17 | $164 |
| Vertex | 5 | $142 |
| Pfizer | 17 | $114 |
| Daiichi Sankyo Inc. | 6 | $94 |
| Averitas Pharma Inc. | 3 | $89 |
| Biodelivery Sciences International, Inc. | 6 | $80 |
| Novartis | 2 | $47 |
| Arbor Pharmaceuticals, Inc. | 3 | $46 |
| Tersera Therapeutics LLC | 2 | $46 |
| Pacira Therapeutics, Inc. | 3 | $44 |
| Lundbeck LLC | 2 | $32 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Neuronetics, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Sentynl Therapeutics, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Virtus Pharmaceuticals LLC | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$226
- WaveWriter Alpha Prime 16$164
- Senza$106
How this compares
$5,763 in reported general payments places this provider in the 55th percentile of 41 interventional pain medicine providers in Tennessee.
See all interventional pain medicine providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,174 | $35,065 |
| Xtampza ErOxycodone Myristate | 48 | $21,125 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 775 | $20,735 |
| LinzessLinaclotide | 23 | $11,851 |
| Lidocaine | 128 | $11,097 |
| Gabapentin | 784 | $9,674 |
| BelbucaBuprenorphine Hcl | 12 | $8,660 |
| Buprenorphine | 30 | $7,372 |
| Pregabalin | 271 | $5,518 |
| Oxycodone Hcl | 311 | $5,067 |
| OxycontinOxycodone Hcl | 14 | $4,840 |
| Morphine Sulfate ErMorphine Sulfate | 145 | $3,612 |
| Tizanidine Hcl | 271 | $3,580 |
| Naloxone Hcl | 48 | $2,471 |
| Diclofenac Sodium | 108 | $2,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $658 | $29,78560 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $18 | $8,33472 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 41 interventional pain medicine providers in Tennessee.
Other interventional pain medicine in Antioch
- John WelkerAntioch$9K
- Daniel McHughAntioch$6K
- Bradley HillAntioch$6K
- Timothy MillerAntioch$4K
- William NewtonWinchester$225K
- Ryan BearerWinchester$35K
- Michael WilkinsonJohnson City$35K
- Jacob MillsMountain Home$24K
- Matthew KangasMemphis$22K
- Matthew RupertFranklin$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.